Standardized Assessment of the Tumor-Stroma Ratio in Colorectal Cancer: Interobserver Validation and Reproducibility of a Potential Prognostic Factor

被引:12
作者
Souza da Silva, Ricella M. [1 ,2 ]
Queiroga, Eduardo M. [3 ]
Paz, Alexandre R. [2 ]
Neves, Fabiana F. P. [4 ]
Cunha, Karin S. [1 ]
Dias, Eliane P. [1 ]
机构
[1] Fluminense Fed Univ, Sch Med, Postgrad Program Pathol, Niteroi, RJ, Brazil
[2] Univ Fed Paraiba, Pathol Anat Serv, Lauro Wanderley Univ Hosp, Joao Pessoa, Paraiba, Brazil
[3] Univ Fed Campina Grande, Alcides Carneiro Univ Hosp, Lab Pathol Anat, Campina Grande, Paraiba, Brazil
[4] Anatomopathol Diag Ctr, Pathol Lab, Joao Pessoa, Paraiba, Brazil
来源
CLINICAL PATHOLOGY | 2021年 / 14卷
关键词
Tumor-stroma ratio; interobserver variability; agreement; colorectal cancer; prognostic factor; INDEPENDENT PREDICTOR; SURVIVAL; BREAST; CARCINOMA; PROPORTION; STATISTICS; PERCENTAGE;
D O I
10.1177/2632010X21989686
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The tumor stroma plays a relevant role in the initiation and evolution of solid tumors. Tumor-stroma ratio (TSR) is a histological feature that expresses the proportion of the stromal component that surrounds cancer cells. In different studies, the TSR represents a potential prognostic factor: a rich stroma in tumor tissue can promote invasion and aggressiveness. The aim of this study was to evaluate the reproducibility and determine the interobserver agreement in the TSR score. The stromal estimate was evaluated in patients diagnosed with colorectal adenocarcinoma (CRA), who underwent surgical resection. We also evaluated age, gender, and other anatomopathological features. Tumor-stroma ratio was calculated based on the slide used in routine diagnostic pathology to determine the T-status. Stromal percentages were separated into 2 categories: <= 50%-low stroma and >50%-high stroma. The interobserver agreement in the TSR scoring was evaluated among 4 pathologists at different stages of professional experience, using 2 different ways to learn the scoring system. In total, 98 patients were included in this study; 54.1% were male, with a mean age of 61.9 years. Localized disease was diagnosed in 60.2% of patients. Stromal-poor CRA was predominant. The concordance between the TSR percentages of the 4 pathologists was substantial (Kappa > 0.6). There was greater agreement among pathologists for stromal-poor tumors. Substantial agreement and high reproducibility were observed in the determination of TSR score. The TSR score is feasible, suggesting that the presented methodology can be used to facilitate the determination of the stromal proportion of potential prognostic factor.
引用
收藏
页数:5
相关论文
共 34 条
  • [1] Amin MB., 2017, AJCC Cancer Staging Manual, V8, DOI [DOI 10.1007/978-3-319-40618-3, 10.1007/978-3-319-40618-3]
  • [2] Abstracts : 31 st European Congress of Pathology
    不详
    [J]. Virchows Archiv, 2019, 475 (Suppl 1) : 1 - 436
  • [3] Morphological consistency of desmoplastic reactions between the primary colorectal cancer lesion and associated metastatic lesions
    Ao, Tadakazu
    Kajiwara, Yoshiki
    Yonemura, Keisuke
    Shinto, Eiji
    Mochizuki, Satsuki
    Okamoto, Koichi
    Kishi, Yoji
    Ueno, Hideki
    [J]. VIRCHOWS ARCHIV, 2020, 477 (01) : 47 - 55
  • [4] Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer
    Chen, Ying
    Zhang, Lei
    Liu, Wenxin
    Liu, Xiangyu
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [5] Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients
    de Kruijf, Esther M.
    van Nes, Johanna G. H.
    de Velde, Cornelis J. H. van
    Putter, Hein
    Smit, Vincent T. H. B. M.
    Liefers, Gerrit Jan
    Kuppen, Peter J. K.
    Tollenaar, Rob A. E. M.
    Mesker, Wilma E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (03) : 687 - 696
  • [6] Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
    Dekker, T. J. A.
    van de Velde, C. J. H.
    van Pelt, G. W.
    Kroep, J. R.
    Julien, J-P.
    Smit, V. T. H. B. M.
    Tollenaar, R. A. E. M.
    Mesker, W. E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 371 - 379
  • [7] Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
    Ferlay, J.
    Colombet, M.
    Soerjomataram, I.
    Dyba, T.
    Randi, G.
    Bettio, M.
    Gavin, A.
    Visser, O.
    Bray, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : 356 - 387
  • [8] The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer
    Gujam, F. J. A.
    Edwards, J.
    Mohammed, Z. M. A.
    Going, J. J.
    McMillan, D. C.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (01) : 157 - 165
  • [9] Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
    Hansen, Torben Frostrup
    Kjaer-Frifeldt, Sanne
    Lindebjerg, Jan
    Rafaelsen, Soren Rafael
    Jensen, Lars Henrik
    Jakobsen, Anders
    Sorensen, Flemming Brandt
    [J]. ACTA ONCOLOGICA, 2018, 57 (04) : 528 - 533
  • [10] The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
    Huijbers, A.
    Tollenaar, R. A. E. M.
    v Pelt, G. W.
    Zeestraten, E. C. M.
    Dutton, S.
    McConkey, C. C.
    Domingo, E.
    Smit, V. T. H. B. M.
    Midgley, R.
    Warren, B. F.
    Johnstone, E. C.
    Kerr, D. J.
    Mesker, W. E.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 179 - 185